Glue versus Laser Ablation in Mini-invasive Pilonidal sinus surgery—the GLAMP study: a study protocol for a randomised controlled trial Authors: Karita Koskinen, Hanna Koppatz, Tuija Poussa, Jukka Harju, Kethe Hermunen Published: 2026 ABSTRACT BackgroundPilonidal sinus disease (PSD) is a chronic acquired condition leading to significant morbidity and healthcare costs in the working-age population. Randomised studies of PSD surgery are rare, and this applies especially to newer mini-invasive techniques. The purpose of our study is to compare two mini-invasive techniques in PSD surgery: laser ablation and fibrin glue treatment.MethodsThis randomised, prospective, multicentre superiority non-blinded study compares two parallel groups of PSD patients treated with laser ablation and fibrin glue. It compares the outcome of these mini-invasive treatment options in regards to both short-term outcome (healing rate) and long-term outcome (recurrence rate), and to the cost of these two treatment options. On the day of surgery, if the operating surgeon indicates that a patient is suitable for laser ablation and glue treatment, that patient is randomly assigned to one of those two surgery groups. After the operation, the operating surgeon completes the examination form. Patients are asked to complete a quality-of-life questionnaire (RAND-36/SF-36) preoperatively and 2 months after surgery. Further, at 2 months, patients also complete an additional questionnaire regarding any discomfort, symptoms, and recovery. All statistical analyses are performed by means of standard statistical software such as SPSS and NCSS.DiscussionIn PSD surgery, very few prospective randomised trials exist, which makes it difficult to compare various surgical methods. Earlier prospective randomised studies involving laser and glue include numbers of patients that are also relatively small, which is why comparisons of methods have not achieved statistical significance. Our study aims to compare two minimally invasive techniques to discover their short- and long-term differences regarding recovery and healing.Trial registrationThis trial was retrospectively registered in ClinicalTrials.gov on April 30, 2025 (NCT06964763). https://clinicaltrials.gov/study/NCT06964763?term=hermunen&rank=1. Administrative information Title {1}Glue versus Laser Ablation in Mini-invasive Pilonidal sinus surgery—the GLAMP study: a study protocol for a randomised controlled trialTrial registration {2a and 2b}The trial was registered in ClinicalTrials.gov on April 30, 2025 (NCT06964763), and is retrospectively registered. https://clinicaltrials.gov/study/NCT06964763?term=hermunen&rank=1Protocol version {3}June 02, 2026; Version 3Funding {4}Researcher-driven research. The study is supported by Orion Research Foundation sr and Medicinska understödsföreningen Liv och Hälsa r.f. Open access is funded by the Helsinki University LibraryAuthor details {5a}K. Koskinen M.D.1,2, H. Koppatz M.D., Ph.D.3, T. Poussa M.Sc. 4, J. Harju M.D., Ph.D.1,2 and K. Hermunen M.D., Ph.D.1,21Faculty of Medicine, University of Helsinki, Helsinki, Finland2Helsinki University Hospital, Abdominal Center, Espoo, Finland3Helsinki University Hospital, Abdominal Center, Hyvinkää, Finland4STAT-Consulting, Nokia, FinlandName and contact information for the trial sponsor {5b}Helsinki University Central HospitalPrincipal investigator: Kethe Hermunen M.D., Ph.D., kethe.hermunen@hus.fiRole of sponsor {5c}Neither of the funding bodies had any involvement in the design of the study, the collection or management of the data, the writing of the report, or the decision to submit the report for publication Title {1}Glue versus Laser Ablation in Mini-invasive Pilonidal sinus surgery—the GLAMP study: a study protocol for a randomised controlled trialTrial registration {2a and 2b}The trial was registered in ClinicalTrials.gov on April 30, 2025 (NCT06964763), and is retrospectively registered. https://clinicaltrials.gov/study/NCT06964763?term=hermunen&rank=1Protocol version {3}June 02, 2026; Version 3Funding {4}Researcher-driven research. The study is supported by Orion Research Foundation sr and Medicinska understödsföreningen Liv och Hälsa r.f. Open access is funded by the Helsinki University LibraryAuthor details {5a}K. Koskinen M.D.1,2, H. Koppatz M.D., Ph.D.3, T. Poussa M.Sc. 4, J. Harju M.D., Ph.D.1,2 and K. Hermunen M.D., Ph.D.1,21Faculty of Medicine, University of Helsinki, Helsinki, Finland2Helsinki University Hospital, Abdominal Center, Espoo, Finland3Helsinki University Hospital, Abdominal Center, Hyvinkää, Finland4STAT-Consulting, Nokia, FinlandName and contact information for the trial sponsor {5b}Helsinki University Central HospitalPrincipal investigator: Kethe Hermunen M.D., Ph.D., kethe.hermunen@hus.fiRole of sponsor {5c}Neither of the funding bodies had any involvement in the design of the study, the collection or management of the data, the writing of the report, or the decision to submit the report for publication K. Koskinen M.D.1,2, H. Koppatz M.D., Ph.D.3, T. Poussa M.Sc. 4, J. Harju M.D., Ph.D.1,2 and K. Hermunen M.D., Ph.D.1,2 1Faculty of Medicine, University of Helsinki, Helsinki, Finland 2Helsinki University Hospital, Abdominal Center, Espoo, Finland 3Helsinki University Hospital, Abdominal Center, Hyvinkää, Finland 4STAT-Consulting, Nokia, Finland Helsinki University Central Hospital Principal investigator: Kethe Hermunen M.D., Ph.D., kethe.hermunen@hus.fi Introduction Background and rationale {6a} Pilonidal sinus disease (PSD) is a chronic acquired condition leading to significant morbidity and healthcare costs in the working-age population [1]. Although many differing treatment methods have been developed, this disease relatively often leads to postoperative complications and recurrence [2]. In recent years, the mini-invasive methods developed to treat PSD include pit-picking [3], treatment with phenol [4], treatment with fibrin glue [5], and endoscopic treatment [6] as well as the Gips technique that uses trephines [7], and with laser ablation [8]. Potential advantages of mini-invasive techniques include performance of the procedure under local anaesthesia, shorter healing time, early return to work, and greater patient satisfaction [9]. The few published non-randomised patient series concern the treatment results of mini-invasive techniques: both fibrin glue [5, 10–12] and laser treatment [14–18]. In fibrin glue studies, patients’ numbers are from 40 to 146, with a success rate after the first operation of 73% to 90%. In laser studies, patients’ numbers are from 40 to 237, with a success rate after the first operation of 85% to 92%. We could find three prospective randomised studies involving laser treatment [13–15]. The first study compared 40 patients, 20 treated with laser therapy, and 20 with the lay-open technique. Findings were that wound healing was significantly faster in the laser group (10.1 ± 2.7 days vs. 34.1 ± 15.1 days, p < 0.0001), but recurrence rates (15% vs. 10%, p = 0.998) between groups during the 12-month follow-up were comparable [13]. In the second study, Demir et al. stated that combining curettage and laser therapy (40 patients) showed better results than curettage alone (40 patients) regarding wound healing at 30 days (17.5% vs. 25%, p = 0.585) and recurrence at 6 months (25.0% vs. 35.0%, p = 0.464) but their findings were not statistically significant [14]. The third study included 30 patients who received laser treatment combined with pit excision, and 28 patients who underwent the Karydakis technique. Their recurrence rates with a mean follow-up of 25 months were 3.3% after the former treatment, and 3.6% after the latter. Regarding fibrin glue, we found randomised studies with varying numbers of patients (from 32 to 132) in which fibrin glue was combined with another surgical method, but not used on its own [16–18]. Altinli et al. compared the Limberg flap technique alone for 16 patients with the Limberg flap technique combined with fibrin sealant for 16 [16]. They concluded that fibrin glue statistically significantly shortens hospitalisation time (2.0 ± 0 days vs. 3.9 ± 0.6 days, p < 0.001) and reduces drainage volume (16.2 ± 13.6 ml vs. 64.4 ± 28.0 ml, p < 0.001). Sözen et al. compared 66 patients treated with the Limberg flap and suction drain to 66 patients treated with the Limberg flap and fibrin glue [17]. The latter patients became mobile earlier (median time to first mobilisation 1 (1–1) vs. 2 (1–2) days, p < 0.001), they returned to work earlier (median duration of incapacity for work 8 (6–12) vs. 17 (15–20) days, p < 0.001), and their wounds healed faster (mean time for complete healing 8.13 ± 7.88 vs. 22.08 ± 8.59 days, p < 0.001) compared to patients treated with Limberg flap and suction drain. In another study, Sözen et al. found that 25 patients treated with the Karydakis technique plus fibrin glue had fewer postoperative fluid collections (8 vs. 24%, p < 0.05) and a shorter hospital stay (mean hospitalisation stay 2.0 vs. 3.7 days) than did the 25 patients treated with the Karydakis technique alone [18]. The prices vary, but for example, in 2021, the price of fibrin glue was 119.20 euros (2 ml) for our hospitals, while the price of laser ablation was 430 euros. Objectives {7} In general, randomised studies involving PSD surgery are rare; this applies especially to newer mini-invasive techniques. Comparison of various surgical techniques requires larger randomised studies. The purpose of our prospective study is to compare two mini-invasive techniques in PSD surgery, namely laser ablation and fibrin glue treatment. Trial design {8} A randomised, prospective multicentre superiority non-blinded study comparing two parallel groups of pilonidal sinus patients treated with mini-invasive surgical techniques. Methods: participants, interventions and outcomes Study setting {9} The study is being carried out in four hospital locations of the Abdominal Center of Helsinki University Hospital (Jorvi Hospital, Porvoo Hospital, Lohja Hospital, and Hyvinkää Hospital). Patients recruited are from these hospitals in the day surgery unit/ambulatory surgical ward. There was no public or patient involvement in the design of the protocol, but the entire research framework has emerged from the ideas of professionals working with patients. Eligibility criteria {10} Patients with a symptomatic primary PSD are eligible. On the day of surgery, if the operating surgeon assesses a patient as being suitable for either the laser ablation or the glue treatment, that patient is randomly assigned to one of the two surgery groups. For a patient to be considered suitable for the study, his or her disease must be sufficiently simple and uncomplicated to allow surgery by a mini-invasive technique. The eligibility is entirely at the discretion of the surgeon, and all surgeons and doctors under specialist training who recruit patients to our GLAMP study have been familiarised with the patient recruitment for the study. The patient is excluded also if he or she has a recurrent disease, is under 18 years of age, is unable to understand written Finnish or Swedish, or if informed consent is unavailable. Who will take informed consent? {26a} The operating surgeon obtains informed consent in writing on the day of surgery. Additional consent provisions for collection and use of participant data and biological specimens {26b} N/A. The study has no additional consent provisions. Interventions Explanation for the choice of comparators {6b} No randomised studies comparing laser treatment and fibrin glue treatment exist, although in PSD surgery, both techniques are frequently used mini-invasive techniques. This study compares the outcome of these two mini-invasive treatment options, both regarding short-term outcomes (healing rate) and long-term outcomes (recurrence rate), and also compares the cost of these two treatment options. Intervention description {11a} Each procedure is performed in the prone position, with preoperative intravenous administration of antibiotics (1.5 g cefuroxime and 0.5 g metronidazole). After identification of the pit openings, each is enlarged with a clamp, and the sinus tracts are examined with a metal probe and then cleaned of debris with a clamp or a curette. Then, for the FiLaC™ (Fistula-tract Laser Closure) procedure, a laser power setting of 13 Watts (W) and the recommended wavelength of 1470 nm diode laser with a 360° emitting fibre is used. The probe is inserted into the sinus tract and withdrawn at 1 mm/second manually. The dose varies between patients depending on the length of the fistula. If the tract fails to close after the first withdrawal, the procedure is repeated. For the patients in the fibrin glue group, sinus tracts are, after cleaning, closed with fibrin glue. Tisseel fibrin sealant (Baxter) 1 ml or 2 ml is used, depending on the length of the fistula, which is applied into the fistula with a syringe. These procedures are performed under local anaesthesia, under total intravenous anaesthesia, or under spinal anaesthesia, with decisions as to method depending on the surgeon, the patient, and the anaesthesiologist. For postoperative pain, the options are oral ibuprofen and paracetamol. After surgery, the operating surgeon completes an examination form. Patients are asked to complete a quality-of-life questionnaire (RAND-36/SF-36) preoperatively and again 2 months after surgery. Further, at 2 months, patients also complete an additional questionnaire regarding possible discomfort, symptoms, and recovery. Criteria for discontinuing or modifying allocated interventions {11b} Patients can refuse to participate in the study, to discontinue their participation, or to withdraw their consent to the study without giving a reason and at any stage of the study. Strategies to improve adherence to interventions {11c} When recruiting subjects, efforts are made to ensure voluntary participation. Subjects receive information on the study from the operating surgeon in as understandable a manner as possible before recruitment. The written study information and instructions for completing the questionnaires are also prepared in as understandable a manner as possible to ensure that subjects understand their commitment. Otherwise, subjects receive the same written information regarding postoperative care as do those patients who do not participate. Relevant concomitant care permitted or prohibited during the trial {11d} N/A. There are no restrictions on the subjects. Provisions for post-trial care {30} Participation in the study causes no harm to any patient. Subjects are only required to complete a short questionnaire by mail 2 months after surgery and to complete a quality-of-life questionnaire both on the day of surgery and 2 months after surgery. Outcomes {12} The purpose of this study is to investigate which mini-invasive surgical technique: laser treatment or fibrin glue treatment, provides a better treatment result, with healing rate at 2 months after surgery as the primary outcome. Healing rate at 2 months is checked using a questionnaire and a treatment phone call. In addition, a follow-up visit is arranged if it is suspected that the surgical area has not healed. In addition, electronic medical record data is checked. The secondary variables are recurrence rate, postoperative complications, duration of recovery from surgery, length of sick leave, return to everyday life, and quality of life (RAND-36/SF). We define PSD recurrence as the reappearance of PSD symptoms following initial complete healing from PSD surgery. PSD with prolonged recovery refers to a condition where the disease does not initially heal after surgery but heals with a delay. Sick leave is prescribed by the operating doctor. The sick leave is always 100%; no partial sick leaves exist for short-term sick leaves in Finland. Secondary variables are assessed using questionnaires completed by the patient on the day of surgery and 2 months after surgery. Data is also collected from the patients' medical records. Patient characteristics including overweight, hair growth in the natal cleft, smoking, and associated diseases (such as diabetes) are included as potential predictive factors. Additional factors analysed are as follows: the potential effects of surgical characteristics (previous opening of an abscess, preoperative lasering of hair in the natal cleft, number of sinuses, spillage of pus, or abscess cavity found during surgery, or senior versus junior surgeon) and centre (four hospitals). On the day of surgery, the operating surgeon fills out a questionnaire including questions about all the aforementioned patient characteristics and additional factors. Participant timeline {13} This study began in September 2023 (Fig. 1).Fig. 1Schedule of patient enrolment, medical interventions, and assessments Schedule of patient enrolment, medical interventions, and assessments Sample size {14} Based on the aforementioned non-randomised studies and the results of an unpublished fibrin glue pilot study that we conducted (10 patients, healing rate at 2 months 100%), we estimate that the healing rate of glue treatment at 2 months is 95% and is 82% after laser treatment. A two-group chi-squared test with a 5% two-sided significance level will have 80% power to detect the difference in healing rate between the fibrin glue treatment and laser treatment (95% vs. 82%) when the sample size in both groups is 94 (nQuery Advisor version 4.0). To allow for some drop-outs, 110 patients will be randomised per group. Recruitment {15} We aim to achieve the desired sample size by collecting study participants from several hospitals. Assignment of interventions: allocation Sequence generation {16a} After the patient’s informed consent, randomisation takes place. Every participating hospital has its own randomisation list (stratified randomisation). Randomisation occurs in groups of ten (block randomisation). A research nurse or a member of the steering committee of each hospital prepares ten envelopes at a time, half of which contain a note saying “laser”, and half saying “glue”. Concealment mechanism {16b} Notes indicating the allocated group are enclosed in sequentially numbered, opaque, sealed envelopes. Implementation {16c} The research nurse generates the allocation sequence and makes up the sealed envelopes. On the day of surgery, if the operating surgeon assesses that the patient is suitable for the study, the patient is randomly assigned to one of the two surgery groups. At the time of inclusion, the envelopes are opened sequentially prior to the operation by the operating surgeon. There is a low likelihood of selection bias since the operating surgeon takes the top envelope from the stack without knowing its sequential numbering. Assignment of interventions: blinding Who will be blinded {17a} After opening of the randomisation envelope, both the patient and the surgeon know each patient’s study group. The study statistician will be blinded. After the main univariable statistical analyses are finished, the code is broken. Procedure for unblinding if needed {17b} N/A. See Sect. 17a. Data collection and management Plans for assessment and collection of outcomes {18a} The data is entered manually from the examination forms and questionnaires. Collection of patient data also requires examination of each patient’s medical records. All patients are followed up through the Finnish healthcare system’s electronic medical records, which provide consistent patient record data. Follow-up will be done by checking the electronic medical records for possible contacts with any of the health providers in Finland. If there are no contacts, we will conclude that the patient does not have any symptoms. If there are contacts, we will monitor symptoms, length of symptoms, new treatment/treatments and recovery after new treatments. Plans to promote participant retention and complete follow-up {18b} In recruiting subjects, efforts are made to ensure voluntary participation. If the patient decides to withdraw his/her consent, the information collected from him/her will serve as a portion of the research data and will be included in statistical analyses as far as possible. Data management {19} Statistical software SPSS serves for data collection, data management, and data verification. This collected data is stored in a locked space accessible only to researchers. The data is stored in a secure environment for 25 years, after which it is properly destroyed. Confidentiality {27} Personal data is processed for scientific research purposes in the public interest in accordance with the EU General Data Protection Regulation and national data protection law. Patient identification data will be removed before data management and statistical analysis. Personal data is processed only to the extent and for the purpose necessary to carry out the research. The collected information and research results are treated confidentially as required by the EU General Data Protection Regulation and national data protection law. All parties and individuals processing the data are bound by confidentiality. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33} N/A. No plans exist for collection, laboratory evaluation, or storage of biological specimens for genetic or molecular analysis in this trial/future use. Statistical methods Statistical methods for primary and secondary outcomes {20a} For all baseline patient characteristics and surgical characteristics, the appropriate summary statistics (total n, mean, geometric mean, median, SD, interquartile range, minimum and maximum) will be available for continuous variables and frequency (percentage) for categorical variables. Primary and secondary endpoints The primary endpoint is the healing rate at 2 months after surgery. Pearson’s chi-squared test serves to compare the two treatment groups. Univariable and multivariable logistic regression analyses will be performed to identify the appropriate predictive factors among patient and surgery characteristics with results given as odds ratios (OR) with 95% confidence intervals. Recurrence rate, postoperative complications, duration of recovery from surgery, length of sick leave, return to everyday life, and quality of life (RAND-36/SF) are the secondary variables. Kaplan–Meier analysis will serve for estimating the recurrence-free rate (%) at various time points after surgery, and the log-rank test for group comparisons. Univariable and multivariable Cox proportional hazards regression models will be used to compare the recurrence-free time between treatment groups. Recurrence-free time is defined as the period from date of operation to date of recurrence. Patients without recurrence are censored at the cut-off date or, when appropriate, at the last follow-up date. Results are given as hazard ratios (HR) with 95% confidence intervals. For other secondary variables, the appropriate univariable and multivariable analyses will be performed by logistic regression, Cox proportional hazards regression, Kaplan–Meier survival curves, ANOVA, or ANCOVA, with non-parametric methods for those categorical variables with a skewed distribution. Covariates Patient characteristics such as overweight, hair growth in the natal cleft, smoking, and associated diseases (such as diabetes) are included as potential predictive factors. Moreover, the potential effects of surgery characteristics (previous opening of an abscess, preoperative lasering of hair in the natal cleft, number of sinuses, spillage of pus or abscess cavity found during the surgery, senior/junior surgeon) and centre (four hospitals) are analyzed. All statistical analyses are performed by means of standard statistical software such as SPSS and NCSS. Interim analyses {21b} No interim analyses are planned. Since no interim analysis is planned, the decision to stop is not based on comparison of the groups. No clinical reason is expected to cause stoppage. The estimated recruitment timeline is 4 years. The principal investigator can prematurely terminate the trial if the progress of the study is unsatisfactory, e.g. the trial would take more than 6 years. Methods for additional analyses (e.g. subgroup analyses) {20b} N/A. No additional analyses are planned. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} Protocol non-adherence is not an important issue in this study. The planned follow-up time is 5 years, and it is not possible to closely monitor the patient protocol adherence. Therefore, the criteria for protocol non-adherence (none, minor, severe) will not be assessed. All patients will be included in the analyses regardless of their potential protocol non-adherence. Thus, the results of this study may approach real-world evidence (RWE), that is, may achieve better generalisability to the general population. The healing rate at 2 months after the surgery is the primary endpoint. Furthermore, at 2 months, quality of life, possible discomfort, symptoms, and recovery will be measured. All these variables will be measured only once after the surgery. Missing values are probably present simultaneously in all those variables. Thus, the missing values will not be imputed. However, for the primary endpoint, as an additional analysis, missing values will be imputed using the method of multiple imputation, and the potential predictors will be found from the group of covariates given in Statistical Methods. Recurrence-free survival is defined as the period from the date of operation to the date of recurrence, and patients without recurrence are censored at the cut-off dates or the last follow-up date when appropriate. Thus, the imputation of missing data is not appropriate. Plans to give access to the full protocol, participant-level data and statistical code {31c} We will allow anonymized data and statistical code to be available to other researchers upon reasonable request, to enable verification and independent analysis. Oversight and monitoring Composition of the coordinating centre and trial steering committee {5d} Four surgeons from each hospital, including the principal investigator, form a steering committee. These surgeons are responsible for data management and send all data from their own hospital to the research nurse, who collects the data. The principal investigator is in regular contact with the other members of the steering committee. The steering committee communicates mainly via e-mail. Composition of the data monitoring committee, its role and reporting structure {21a} An independent Data Monitoring Committee was considered and deemed unnecessary, because this is a low-risk intervention study. The data controller in the study is the Hospital District of Helsinki and Uusimaa, which is responsible for the legality of the processing of personal data in connection with the study. Adverse event reporting and harms {22} Patients are insured against damage that occurs in the hospital. Frequency and plans for auditing trial conduct {23} The study is approved by the institutional review board and the Ethics Committee of Helsinki University Hospital (authorisation number HUS/2951/2021). The institutional review board and the Ethics Committee of Helsinki University Hospital do not offer auditing. Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethics committees) {25} The sponsor and funder are immediately informed of any protocol amendments, and the principal investigator then informs the steering committee members. The Clinical Trial Registry is updated for important changes, and in the case of any major protocol modification, an amendment to the research permit from the institutional review board and the Ethics Committee of Helsinki University Hospital must also be applied for. All deviations from the protocol are documented. Dissemination plans {31a} The trial results will be published as articles in scientific journals. Discussion In PSD surgery, prospective randomised trials are very few, which makes it difficult to compare among surgical methods. In prospective randomised studies involving laser and glue, numbers of patients are also relatively small, which is why no statistical significance has been achieved in method comparisons. Our study aims to compare two mini-invasive techniques and to discover short and long-term differences between the two regarding recovery and healing. Trial status Protocol version 1 August 2, 2025. Recruitment began on September 1, 2023, and completion is predicted to occur during 2029.